glp-1 obesity drug news oct 21 2025 Weight Loss Enforcement in 2025: State Attorneys General Step into a Growing Regulatory Gap GLP-1 Weight-Loss Drug Demonstration Begins
Description
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): A randomised, placebo-controlled trial
DAlessio, Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease
GLP-1 receptor agonist ameliorates experimental lung fibrosis
GLP-1 receptor agonists represent a hard-earned pharmacological breakthrough, offering potent glucose control and unprecedented weight loss
Limited competition and supply constraints exacerbate cost pressures, impacting health plans and patients
